Despite advances in the management of the disease, outcomes remain poor for patients with advanced epithelial ovarian cancer.

Dallas, TX -- (SBWire) -- 08/13/2010 -- ReportsandReports announce it will carry Stakeholder Opinions: Ovarian Cancer - Approaching the era of molecular targeted therapy Market Research Report in its Store.

Browse complete Report on: http://www.reportsandreports.com/market-reports/stakeholder-opinions-ovarian-cancer-approaching-the-era-of-mol/

Despite advances in the management of the disease, outcomes remain poor for patients with advanced epithelial ovarian cancer. The high level of unmet need, coupled with the large size of the patient population, is driving extensive R&D interest in this indication. The anticipated incorporation of molecular targeted therapies into treatment is expected to improve patient outcomes in the future.

Scope

• Ovarian cancer overview, including disease definition, epidemiology, discussion of unmet needs, and market potential
• Current treatment options for ovarian cancer and ongoing controversies
• Examination of the late-phase ovarian cancer pipeline, including drug profiles of late-stage agents
• Stakeholder opinions based on qualitative interviews with key opinion leaders from the US and EU

Highlights

Ovarian cancer is the leading cause of death from gynecological malignancies in the Western world. This is because the majority of epithelial ovarian cancer patients present with advanced disease at diagnosis, where treatment has a palliative rather than curative intent.

While first-line platinum-based chemotherapy can result in high response rates of over 70-80%, the majority of patients will advanced epithelial ovarian cancer will eventually relapse with incurable disease. As such, there is a need for novel first-line therapies to improve survival rates.

R&D interest in ovarian cancer is high. There are currently 85 drugs in the pipeline, which is dominated by molecular targeted therapies (42%) and cytotoxic therapies (33%). Competition for the approval of the first molecular targeted therapy in ovarian cancer is fierce.

Reasons to Purchase

• Estimate the number of treatable patients and identify unmet needs for future drug development opportunities
• Understand the current treatment of the disease, as well as opportunities and threats in the ovarian cancer market
• Analyze the current ovarian cancer pipeline and the potential of late-stage drugs

Table Of contents

Overview
Catalyst 1
Summary 1
About Datamonitor healthcare 2
About the Oncology pharmaceutical analysis team 2
Executive Summary 3
Scope of the analysis 3
Datamonitor insight into the ovarian cancer market 3
Related reports 4
Upcoming reports 4
Table of Contents 5
Patient Potential 6
Key findings 6
Definition 6
Epithelial tumors 7
The vast majority of ovarian cancers are epithelial in origin 7
The majority of epithelial ovarian cancers are sporadic in nature 8
Germ cell tumors 8
Sex cord-stromal tumors 8
A successful screening test for ovarian cancer has not been developed 8
Ovarian cancer is a surgically staged malignancy 9
Epidemiology 12
The incidence of ovarian cancer in the seven major markets is forecast to reach nearly 63,000 cases by 2019 12
The highest ovarian cancer rates prevail in Northern European countries 14
Current treatment options 15
Most early-stage patients are treated with surgery and chemotherapy 15
Surgery has a central role in the management of advanced disease 16
First-line platinum-based chemotherapy is the standard of care for advanced disease 17
The use of intraperitoneal chemotherapy remains controversial 20
Maintenance therapy has not been shown to improve overall survival 21
The treatment of recurrent disease is rarely curative and depends on patients' platinum sensitivity 22
Platinum-based combination chemotherapy is recommended for platinum-sensitive recurrent disease 23
A number of single agents can be used in the treatment of platinum-resistant recurrent disease 25
Unmet need 25
More effective agents are required for the treatment of advanced disease 25
An effective screening test could significantly improve patient survival 26
R&D efforts should be directed towards molecular targeted therapies 26
Less invasive surgical approaches should be explored for early-stage patients 27
Market potential 28
Key findings 28
Current market overview 28
Opportunities and threats 29
Opportunities 29
Significant unmet need remains in the treatment of advanced disease 29
There is increased interest in the development of molecular targeted therapies 30
There is a large patient base in ovarian cancer, and a high commercial attractiveness 30
Threats 30
The development of an effective screening modality could decrease the patient base 30
Pipeline Analysis 31
Key findings 31
Ovarian cancer pipeline overview 31
Ovarian cancer late-phase pipeline 37
Avastin (bevacizumab; Genentech/Roche/Chugai) 37
Drug profile 37
Development overview 38
Product positioning 41
SWOT analysis 42
Karenitecin (cositecan; BNP-1350; BioNumerik) 43
Drug profile 43
Development overview 44
Product positioning 46
SWOT analysis 47
Opaxio (paclitaxel poliglumex; Cell Therapeutics/Novartis) 47
Drug profile 48
Development overview 48
Product positioning 49
SWOT analysis 50
Paclical (micellar paclitaxel formulation; Oasmia) 52
Drug profile 52
Development overview 52
Product positioning 53
SWOT analysis 54
Tarceva (erlotinib; Genentech/Roche/Chugai/OSI) 55
Drug profile 55
Development overview 55
Product positioning 58
SWOT analysis 59
Vargatef (intedanib; BIBF-1120; Boehringer Ingelheim) 60
Drug profile 60
Development overview 61
Product positioning 62
SWOT analysis 63
Votrient (pazopanib; GlaxoSmithKline) 63
Drug profile 63
Development overview 64
Product positioning 67
SWOT analysis 68
Farletuzumab (MORAb-003; Morphotek/Eisai) 69
Drug profile 69
Development overview 70
Product positioning 73
SWOT analysis 74
Abagovomab (Menarini/Cell Control Biomedical) 74
Drug profile 74
Development overview 75
Product positioning 77
SWOT analysis 77
Bibliography 79
Journals 79
Websites 84
Datamonitor reports 86

Appendix
Contributing experts 87
Report methodology 87
About Datamonitor 87
About Datamonitor Healthcare 87
About the Oncology analysis team 88
Disclaimer 90

Browse complete Report on: http://www.reportsandreports.com/market-reports/stakeholder-opinions-ovarian-cancer-approaching-the-era-of-mol/

Browse all Healthcare Market Research Reports on:
http://www.reportsandreports.com/market-research/healthcare/

Browse all Datamonitor Market Research Reports RSS on:
http://www.reportsandreports.com/Publishers/datamonitor/

Browse all Latest Report on:
http://www.reportsandreports.com/LatestReport.aspx

Related Reports:

Stakeholder Opinions: Gastric Cancer - Targeted therapies compete for first-to-market status
http://www.reportsandreports.com/market-reports/stakeholder-opinions-gastric-cancer-targeted-therapies-compete/

Commercial Insight: Molecular Targeted Cancer Therapies
http://www.reportsandreports.com/market-reports/commercial-insight-molecular-targeted-cancer-therapies-leadin/

Pipeline Insight: Prostate Cancer Molecular targeted therapies will fulfill unmet needs in castration-resistant disease
http://www.reportsandreports.com/market-reports/pipeline-insight-prostate-cancer-molecular-targeted-therapies-w/

About Us:
Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.

Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Website: http://www.reportsandreports.com/
Blog: http://reportsnreports.wordpress.com/
Blog: http://reportsandreports.blogspot.com/